Influence of medical conditions on the diagnostic accuracy of plasma p‐tau217 and p‐tau217/Aβ42
Alzheimer s & Dementia,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 6, 2024
Abstract
INTRODUCTION
Blood‐based
biomarkers
(BBMs)
can
enable
early
detection
of
brain
amyloid
beta
(Aβ)
pathology
in
cognitively
unimpaired
individuals.
However,
the
extent
to
which
common
medical
conditions
affect
biomarker
performance
remains
unclear.
METHODS
Participants
(
n
=
348)
included
individuals
without
cognitive
impairment.
We
studied
how
Aβ
associated
with
BBMs
(Aβ42/40,
phosphorylated
tau
[p‐tau]
181
and
217,
p‐tau217/Aβ42,
glial
fibrillary
acidic
protein
[GFAP],
neurofilament
light
[NfL])
optimal
BBM
thresholds
for
predicting
positivity
whether
they
are
obscured
by
presence
conditions.
RESULTS
Plasma
Aβ42/40,
p‐tau181,
p‐tau217,
GFAP,
but
not
NfL,
were
significantly
Aβ.
P‐tau217/Aβ42
showed
best
discriminative
(area
under
curve:
0.91).
The
strength
p‐tau217–brain
associations
diabetes
cardiovascular
DISCUSSION
These
results
suggest
may
help
detect
caution
their
use
due
that
could
accuracy.
Highlights
GFAP
NfL
significant
more
strongly
level
those
(AUC
0.91)
discriminating
an
cut‐off
>1.2,
followed
p‐tau217
at
>0.46
pg/mL,
slightly
improving
when
excluding
participants
Language: Английский
Blood biomarkers differentiate AD‐related versus non‐AD‐related cognitive deficits
Alzheimer s & Dementia,
Journal Year:
2025,
Volume and Issue:
21(3)
Published: March 1, 2025
Abstract
INTRODUCTION
The
utility
of
blood‐based
biomarkers
for
discriminating
Alzheimer's
disease
(AD)‐related
versus
non‐AD‐related
cognitive
deficits
in
preclinical
populations
remains
poorly
understood.
Here,
we
tested
the
capability
blood
markers
to
detect
and
discriminate
variation
performance
across
multiple
domains
a
cognitively
unimpaired
sample.
METHODS
Participants
(
n
=
648,
aged
69.9
±
3.8,
71%
female)
underwent
comprehensive
assessment
assays
plasma‐based
amyloid
beta
(Aβ)1‐42/1‐40
by
mass
spectrometry,
phosphorylated
tau
(p‐tau)
181
217,
p‐tau217/Aβ1‐42,
glial
fibrillary
acidic
protein
(GFAP),
neurofilament
light
(NfL).
RESULTS
Greater
p‐tau217
was
exclusively
associated
with
poorer
episodic
memory
(β
−0.11,
SE
0.04,
p
.003),
remained
so
after
covarying
NfL.
Higher
NfL
non‐specifically
range
p‐tau217.
DISCUSSION
Blood‐based
may
differentiate
AD‐related
deficits.
This
characterization
will
be
important
early
intervention
monitoring
AD.
Highlights
There
is
heterogeneity
causes
decline
aging.
help
characterize
these
causes.
Elevated
memory.
cognition
broad
domains.
Blood
AD‐
Language: Английский